Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Cut by Perceptive Advisors LLC

Perceptive Advisors LLC lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 3.6% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,862,608 shares of the company’s stock after selling 70,151 shares during the period. Vaxcyte comprises approximately 3.3% of Perceptive Advisors LLC’s investment portfolio, making the stock its 7th biggest holding. Perceptive Advisors LLC’s holdings in Vaxcyte were worth $140,646,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PCVX. Parallel Advisors LLC raised its stake in Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after acquiring an additional 250 shares during the period. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at approximately $35,000. Fidelis Capital Partners LLC bought a new position in Vaxcyte in the 1st quarter worth approximately $37,000. J.Safra Asset Management Corp grew its stake in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after buying an additional 526 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in Vaxcyte during the 2nd quarter valued at $70,000. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Up 1.5 %

Vaxcyte stock opened at $113.14 on Monday. The firm has a fifty day simple moving average of $92.24 and a two-hundred day simple moving average of $77.87. Vaxcyte, Inc. has a twelve month low of $44.20 and a twelve month high of $121.06. The company has a market capitalization of $12.63 billion, a PE ratio of -26.43 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the business earned ($0.70) earnings per share. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Leerink Partners boosted their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a report on Tuesday, September 3rd. Needham & Company LLC increased their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Mizuho lifted their price objective on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. BTIG Research upped their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group lifted their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte has an average rating of “Buy” and a consensus target price of $147.50.

Insider Activity

In related news, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,017,840. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at $1,017,840. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,479,005.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,000 shares of company stock worth $6,508,130. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.